文献速递妇科

Ⅰ期子宫内膜癌女性的孤立性阴道复发

Isolated vaginal recurrence in women with stage I endometrial cancer.
PubMed 文献 · Gynecol Oncol · 2023-10-20

本研究比较了两大癌症中心2815例手术Ⅰ期子宫内膜癌患者中孤立性阴道复发与阴道外复发的临床病理特征,278例(10%)复发,其中61例(2%)为孤立性阴道复发,42例(69%)位于阴道顶端,孤立性阴道复发中位时间11个月早于阴道外复发的20个月(P<.004),手术方式未见影响复发,辅助阴道近距离放疗后孤立性阴道顶端复发风险为1%-2%。

要点

  • 孤立性阴道复发(2%)中69%位于阴道顶端,中位复发时间11个月,早于阴道外复发的20个月(P<.004)。
  • 辅助阴道近距离放疗后孤立性阴道复发19例(2%),其中16例(84%)位于阴道顶端。
  • 微创手术与开腹手术的3年无进展生存率无显著差异(孤立性阴道复发97.6% vs 96.9%,P=.8)。

核心结论

  • Ⅰ期子宫内膜癌的孤立性阴道复发较非阴道复发检出更早,手术方式似乎不影响复发,原发手术后辅助阴道近距离放疗的孤立性阴道顶端复发风险为1%-2%。

研究设计与样本

  • 在2009年1月1日至2017年12月31日期间于两家大型癌症中心接受治疗的2009年国际妇产科联盟(FIGO)Ⅰ期子宫内膜癌患者被纳入,排除肉瘤组织学类型,复发分为孤立性阴道复发与阴道外复发,采用卡方分析及Kaplan-Meier曲线与对数秩检验比较临床和病理变量。

主要发现

  • 2815例中278例(10%)复发,61例(2%)为孤立性阴道复发,其中42例(69%)位于阴道顶端;217例(8%)为阴道外复发,其中18例含阴道成分。
  • 孤立性阴道复发的中位复发时间为11个月(范围1-68),阴道外复发为20个月(范围1-98),P<.004。
  • 960例(34%)接受辅助阴道近距离放疗(VBT),其中156例(16%)复发,19例(2%)为孤立性阴道复发,包括16例(84%)位于阴道顶端。
  • 微创手术(MIS)与开腹手术的3年无进展生存率:孤立性阴道复发为97.6%(标准误±0.4%)vs 96.9%(标准误±1.1%),P=.8;阴道外复发为91.8%(标准误±0.7%)vs 90.8%(标准误±1.8%),P=.8。

关键数值与推荐

  • 2815例中278例(10%)复发,孤立性阴道复发61例(2%),阴道外复发217例(8%)。
  • 孤立性阴道复发中位时间11个月(范围1-68)vs 阴道外复发20个月(范围1-98),P<.004。
  • 辅助VBT后孤立性阴道顶端复发风险为1%-2%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare clinical and pathologic characteristics of women with surgical stage I endometrial carcinoma by location of first recurrence and describe characteristics of isolated vaginal recurrence. METHODS: Patients with 2009 International Federation of Obstetrics and Gynecology (FIGO) stage I endometrial carcinoma treated at two large cancer centers from 1/1/2009-12/31/2017 were identified. Sarcoma histology was excluded. Recurrences were grouped into isolated vaginal or extravaginal. Isolated vaginal recurrences were localized by anatomic location within the vaginal vault. Clinical and pathologic variables were compared with chi-square analysis, and Kaplan-Meier curves with log-rank tests. RESULTS: Of 2815 women identified, 278 (10%) experienced a recurrence. Sixty-one patients (2%) had an isolated vaginal recurrence, including 42 (69%) at the vaginal apex; 217 (8%) had an extravaginal recurrence, including 18 with a vaginal component. Median time to recurrence was 11 months (range, 1-68) for isolated vaginal recurrence and 20 months (range, 1-98) for extravaginal recurrence (P < .004). Of 960 patients (34%) treated with adjuvant vaginal brachytherapy (VBT), 156 (16%) recurred; 19 (2%) had an isolated vaginal recurrence, including 16 (84%) at the vaginal apex. Three-year PFS rates for isolated vaginal recurrence were 97.6% (SE ± 0.4%) with minimally invasive surgery (MIS) versus 96.9% (SE ± 1.1%) with open (P = .8), and for extravaginal recurrence were 91.8% (SE ± 0.7%) with MIS versus 90.8% (SE ± 1.8%) with open (P = .8). CONCLUSIONS: Isolated vaginal recurrences in stage I endometrial cancer are detected earlier than non-vaginal recurrences. Surgical approach does not appear to impact recurrence. Adjuvant VBT after primary surgery carries a 1%-2% risk of isolated vaginal apex recurrence.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Rios-Doria E, Cun HT, Filippova OT, et al. Isolated vaginal recurrence in women with stage I endometrial cancer. Gynecol Oncol. 2023. PMID: 37864854. doi:10.1016/j.ygyno.2023.10.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。